These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 18294295)

  • 1. Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia.
    Kiyotani K; Mushiroda T; Kubo M; Zembutsu H; Sugiyama Y; Nakamura Y
    Cancer Sci; 2008 May; 99(5):967-72. PubMed ID: 18294295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of CYP3A4, CYP3A5, ABCB1, ABCC2, ABCG2 and SLCO1B3 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of docetaxel in nasopharyngeal carcinoma patients.
    Chew SC; Singh O; Chen X; Ramasamy RD; Kulkarni T; Lee EJ; Tan EH; Lim WT; Chowbay B
    Cancer Chemother Pharmacol; 2011 Jun; 67(6):1471-8. PubMed ID: 21468756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia: CALGB 60805 (Alliance).
    Lewis LD; Miller AA; Owzar K; Bies RR; Markova S; Jiang C; Kroetz DL; Egorin MJ; McLeod HL; Ratain MJ;
    Pharmacogenet Genomics; 2013 Jan; 23(1):29-33. PubMed ID: 23188068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients.
    Miura M; Satoh S; Inoue K; Kagaya H; Saito M; Inoue T; Suzuki T; Habuchi T
    Eur J Clin Pharmacol; 2007 Dec; 63(12):1161-9. PubMed ID: 17906856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic Variations of Drug Transporters Can Influence on Drug Response in Patients Treated with Docetaxel Chemotherapy.
    Choi JR; Kim JO; Kang DR; Shin JY; Zhang XH; Oh JE; Park JY; Kim KA; Kang JH
    Cancer Res Treat; 2015 Jul; 47(3):509-17. PubMed ID: 25648089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association study of genetic polymorphisms of drug transporters, SLCO1B1, SLCO1B3 and ABCC2, in African-Americans, Hispanics and Caucasians and olmesartan exposure.
    Endo S; Fukahori A; Tokuhiro S; Shinagawa A; Walker J; Yoshihara K; Ishizuka H; Ieiri I; Sugiyama Y
    J Hum Genet; 2012 Aug; 57(8):531-44. PubMed ID: 22695893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of SLCO1B3 haplotype-tag SNPs on docetaxel disposition in Chinese nasopharyngeal cancer patients.
    Chew SC; Sandanaraj E; Singh O; Chen X; Tan EH; Lim WT; Lee EJ; Chowbay B
    Br J Clin Pharmacol; 2012 Apr; 73(4):606-18. PubMed ID: 21995462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective evaluation of the drug-metabolizing enzyme polymorphisms and toxicity profile of docetaxel in Korean patients with operable lymph node-positive breast cancer receiving adjuvant chemotherapy.
    Kim KP; Ahn JH; Kim SB; Jung KH; Yoon DH; Lee JS; Ahn SH
    Cancer Chemother Pharmacol; 2012 May; 69(5):1221-7. PubMed ID: 22271208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic variation in the ATP binding cassette transporter ABCC10 is associated with neutropenia for docetaxel in Japanese lung cancer patients cohort.
    Sone K; Oguri T; Uemura T; Takeuchi A; Fukuda S; Takakuwa O; Maeno K; Fukumitsu K; Kanemitsu Y; Ohkubo H; Takemura M; Ito Y; Niimi A
    BMC Cancer; 2019 Mar; 19(1):246. PubMed ID: 30890141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ABCB1 and ABCC2 genetic polymorphism as risk factors for neutropenia in esophageal cancer patients treated with docetaxel, cisplatin, and 5-fluorouracil chemotherapy.
    Nomura H; Tsuji D; Demachi K; Mochizuki N; Matsuzawa H; Yano T; Daiko H; Fujii S; Kojima T; Itoh K; Kawasaki T
    Cancer Chemother Pharmacol; 2020 Aug; 86(2):315-324. PubMed ID: 32748110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia.
    Yamakawa Y; Hamada A; Nakashima R; Yuki M; Hirayama C; Kawaguchi T; Saito H
    Ther Drug Monit; 2011 Apr; 33(2):244-50. PubMed ID: 21311410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Associations of genetic polymorphisms of the transporters organic cation transporter 2 (OCT2), multidrug and toxin extrusion 1 (MATE1), and ATP-binding cassette subfamily C member 2 (ABCC2) with platinum-based chemotherapy response and toxicity in non-small cell lung cancer patients.
    Qian CY; Zheng Y; Wang Y; Chen J; Liu JY; Zhou HH; Yin JY; Liu ZQ
    Chin J Cancer; 2016 Sep; 35(1):85. PubMed ID: 27590272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The association of the UGT1A8, SLCO1B3 and ABCC2/ABCG2 genetic polymorphisms with the pharmacokinetics of mycophenolic acid and its phenolic glucuronide metabolite in Chinese individuals.
    Geng F; Jiao Z; Dao YJ; Qiu XY; Ding JJ; Shi XJ; Li ZD; Zhong MK
    Clin Chim Acta; 2012 Apr; 413(7-8):683-90. PubMed ID: 22227166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Allelic Interaction of Single Nucleotide Polymorphisms of Influx and Efflux Transporters Genes With Nonhematologic Adverse Events of Docetaxel in Breast Cancer Patients.
    Jabir RS; Ho GF; Annuar MABA; Stanslas J
    Clin Breast Cancer; 2018 Oct; 18(5):e1173-e1179. PubMed ID: 29885788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of genetic variants in UGT1A1, SLCO1B3, ABCB1, ABCC2, ABCG2, ORM1 on PK/PD of telmisartan in Chinese patients with mild to moderate essential hypertension
.
    Pei Q; Yang L; Tan HY; Liu SK; Liu Y; Huang L; Li RH; Wan Q; Huang J; Guo CX; Zuo XC; Li J; Yang GP
    Int J Clin Pharmacol Ther; 2017 Aug; 55(8):659-665. PubMed ID: 28518053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of SLCO1B3 drives taxane resistance in prostate cancer.
    de Morrée ES; Böttcher R; van Soest RJ; Aghai A; de Ridder CM; Gibson AA; Mathijssen RH; Burger H; Wiemer EA; Sparreboom A; de Wit R; van Weerden WM
    Br J Cancer; 2016 Sep; 115(6):674-81. PubMed ID: 27537383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association study of genetic polymorphism in ABCC4 with cyclophosphamide-induced adverse drug reactions in breast cancer patients.
    Low SK; Kiyotani K; Mushiroda T; Daigo Y; Nakamura Y; Zembutsu H
    J Hum Genet; 2009 Oct; 54(10):564-71. PubMed ID: 19696793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genome-wide association study of epirubicin-induced leukopenia in Japanese patients.
    Srinivasan Y; Sasa M; Honda J; Takahashi A; Uno S; Kamatani N; Kubo M; Nakamura Y; Zembutsu H
    Pharmacogenet Genomics; 2011 Sep; 21(9):552-8. PubMed ID: 21799462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between SLCO1B3 and ABCA3 polymorphisms and imatinib response in chronic myeloid leukemia patients.
    de Lima LT; Bueno CT; Vivona D; Hirata RD; Hirata MH; Hungria VT; Chiattone CS; Zanichelli MA; Chauffaille Mde L; Guerra-Shinohara EM
    Hematology; 2015 Apr; 20(3):137-42. PubMed ID: 25056761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 expression and pravastatin pharmacokinetics.
    Niemi M; Arnold KA; Backman JT; Pasanen MK; Gödtel-Armbrust U; Wojnowski L; Zanger UM; Neuvonen PJ; Eichelbaum M; Kivistö KT; Lang T
    Pharmacogenet Genomics; 2006 Nov; 16(11):801-8. PubMed ID: 17047488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.